A Review of Pancreatic Cancer: Epidemiology, Genetics, Screening, and Management
DOI:
https://doi.org/10.3889/oamjms.2019.104Keywords:
Pancreatic Cancer, Epidemiology, Genetics, Diagnostic Radiology, Interventional Radiology, Pancreatic cancer managementAbstract
Pancreatic cancer ranks among the causes of cancer-related deaths. The average size of pancreatic cancer during diagnosis is about 31 mm and has not changed significantly over the past 30 years. Poor early diagnosis of a tumour has been attributed to the late-presenting symptoms. Over the years, improvement in the diagnosis of pancreatic cancer has been observed, and this can be linked to advancement in imaging techniques as well as the increasing knowledge of cancer history and genetics. Magnetic Resonance Imaging, Endoscopic Ultrasound, and Computer Topography are the approved imaging modalities utilised in the diagnosing of pancreatic cancer. Over the years, the management of patients with pancreatic cancer has seen remarkable improvement as reliable techniques can now be harnessed and implemented in determining the resectability of cancer. However, only about 10% of pancreatic adenocarcinomas are resectable at the time of diagnosis and will highly benefit from a microscopic margin-negative surgical resection. Overall, the failure of early tumour identification will result in considerable morbidity and mortality.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Xu Y-P. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol. 2016; 8(2):165. https://doi.org/10.4251/wjgo.v8.i2.165 PMid:26909131 PMCid:PMC4753167
American Cancer Society. Cancer Facts and Figures 2017. Genes Dev. 2017; 21(20):2525–38.
Dragovich T, Espat J, Erickson R. Pancreatic Cancer Clinical Presentation: History, Physical Examination. Medscape. 2017.
Puleo F. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol. 2015; 21(8):2281. https://doi.org/10.3748/wjg.v21.i8.2281 PMid:25741134 PMCid:PMC4342903
Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol. 2014; 20(24):7864–77. https://doi.org/10.3748/wjg.v20.i24.7864 PMid:24976723 PMCid:PMC4069314
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7–30. https://doi.org/10.3322/caac.21442 PMid:29313949
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359–86. https://doi.org/10.1002/ijc.29210 PMid:25220842
Cai Y, Li X, Shen P, Zhang D. CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma. Biol Res. 2018; 51(1):1–9. https://doi.org/10.1186/s40659-017-0149-0 PMid:29298720 PMCid:PMC5751927
Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn J-C. Current Knowledge on Pancreatic Cancer. Front Oncol. 2012; 2:1–24. https://doi.org/10.3389/fonc.2012.00006 PMid:22655256 PMCid:PMC3356035
Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M, et al. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. Oncotarget. 2014; 5(13):5100–12. https://doi.org/10.18632/oncotarget.2087 PMid:24947996 PMCid:PMC4148125
Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Oncotarget. 2017; 8(11):17945–59. https://doi.org/10.18632/oncotarget.14901 PMid:28160547 PMCid:PMC5392299
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JJ, Hruban RH, et al. Hypermethylation of Multiple Genes in Pancreatic Adenocarcinoma Hypermethylation of Multiple Genes in Pancreatic Adenocarcinoma 1. Cancer Res. 2000; 60(410):1835–9. PMid:10766168
Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit. 2006; 12(9):RA186-93. PMid:16940943
Pelosi E, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines. 2017; 5(4):65. https://doi.org/10.3390/biomedicines5040065 PMid:29156578 PMCid:PMC5744089
Sipos B, Sperveslage J, Anlauf M, Hoffmeister M, Henopp T, Buch S, et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J Clin Endocrinol Metab. 2015; 100(5):E783–8. https://doi.org/10.1210/jc.2014-4405 PMid:25695890
Hackeng WM, Hruban RH, Offerhaus GJA, Brosens LAA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol. 2016; 11(1):1–17. https://doi.org/10.1186/s13000-016-0497-z PMid:27267993 PMCid:PMC4897815
Jiao Y, Shi C, Edil BH, Wilde RF De, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1 and mTOR Pathway Genes are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science (80). 2011; 331(6021):1199–203. https://doi.org/10.1126/science.1200609 PMid:21252315 PMCid:PMC3144496
Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, et al. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci. 2014; 111(23):E2404–13. https://doi.org/10.1073/pnas.1319962111 PMid:24912192 PMCid:PMC4060701
House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, et al. Aberrant Hypermethylation of Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms. Trans. Meet Am Surg Assoc. 2003; 121(3):117–26.
Mayo Clinic. CT scan [Internet]. Mayo Foundation for Education and Research. 2015.
Allen VB DB. Cochrane Database of Systematic Reviews Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer (Review) Diagnostic accuracy of laparoscopy. Cochrane Database Syst Rev Art. 2016; (7):11–20.
Wilson JM, Mukherjee S, Brunner TB, Partridge M, Hawkins MA. Correlation of18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. Clin Oncol. 2017; 29(6):370–7. https://doi.org/10.1016/j.clon.2017.01.038 PMid:28190636 PMCid:PMC5429392
Wilson JM, Mukherjee S, Brunner TB, Partridge M, Hawkins MA. Correlation of18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. Clin Oncol. 2017; 29(6):370–7. https://doi.org/10.1016/j.clon.2017.01.038 PMid:28190636 PMCid:PMC5429392
Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, et al. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET–CT) in follow-up of curatively resected pancreatic cancer patients. Hpb. 2016; 18(1):57–64. https://doi.org/10.1016/j.hpb.2015.06.001 PMid:26776852 PMCid:PMC4750231
Stemkens B, Tijssen RH, de Senneville BD, Heerkens HD, van Vulpen M, Lagendijk JJ, et al. Optimizing 4-dimensional magnetic resonance imaging data sampling for respiratory motion analysis of pancreatic tumors. Int J Radiat Oncol Biol Phys. 2015; 91(3):571–8. https://doi.org/10.1016/j.ijrobp.2014.10.050 PMid:25596109
Dababou S, Marrocchio C, Rosenberg J, Bitton R, Pauly KB, Napoli A, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Ther Ultrasound. 2017; 5(1):9. https://doi.org/10.1186/s40349-017-0080-4 PMid:28373906 PMCid:PMC5376281
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013; 62(3):339–47. https://doi.org/10.1136/gutjnl-2012-303108 PMid:23135763 PMCid:PMC3585492
Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. Risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2008; 25(11):1417–22. https://doi.org/10.1200/JCO.2006.09.2452 PMid:17416862 PMCid:PMC2267288
Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, et al. Familial pancreatic cancer: Concept, management and issues. World J Gastroenterol. 2017; 23(6):935–48. https://doi.org/10.3748/wjg.v23.i6.935 PMid:28246467 PMCid:PMC5311103
Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64(7):2634–8. https://doi.org/10.1158/0008-5472.CAN-03-3823 PMid:15059921
Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: Current and evolving therapies. Int J Mol Sci. 2017; 18(7). https://doi.org/10.3390/ijms18071338 PMid:28640192 PMCid:PMC5535831
Chang, Wu, Yang, et al. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Am J Cancer Res. 2017; 7(2):357–69. PMid:28337383 PMCid:PMC5336508
Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA - J Am Med Assoc. 2016; 315(17):1844–53. https://doi.org/10.1001/jama.2016.4324 PMid:27139057
Chang J, Schomer D, Dragovich T. Anatomical, physiological, and molecular imaging for pancreatic cancer: Current clinical use and future implications. Biomed Res Int. 2015; 2015:1–7. https://doi.org/10.1155/2015/269641
Mckenna S EM. The Medical Management of Pancreatic Cancer: A Review. Oncologist. 2003; 2003(8):149–60. https://doi.org/10.1634/theoncologist.8-2-149
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Samuel Idachaba, Oluwafemi Dada, Olalekan Abimbola, Olamide Olayinka, Akunnaya Uma, Esther Olunu, Adegbenro Omotuyi John Fakoya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
